Related Experiment Video
Updated: Jun 25, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Emerging treatments in acute lymphoblastic leukemia
1Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Tyrol, Ausria. roman.crazzolara@i-med.ac.at
Current Cancer Drug Targets
|February 10, 2009
Summary
Novel therapies are being developed to combat acute lymphoblastic leukemia (ALL), a cancer affecting both children and adults. This review focuses on small molecular inhibitors targeting ALL pathways to overcome chemotherapy resistance and improve outcomes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute lymphoblastic leukemia (ALL) is a cancer of early B- and T-lymphocyte progenitors.
- While pediatric ALL outcomes have improved, adult ALL survival rates remain poor at 40% long-term.
- Chemotherapy resistance and treatment complications are significant challenges in ALL management.
Purpose of the Study:
- To review the current development of novel anti-leukemic agents for ALL.
- To emphasize small molecular inhibitors in clinical trials and preclinical development.
- To discuss challenges in the development of new ALL treatment strategies.
Main Methods:
- Review of current research on novel anti-leukemic agents.
- Focus on small molecular inhibitors targeting ALL-specific pathways.
- Analysis of agents in clinical trials and advanced preclinical stages.
Main Results:
- New drugs are being designed to interfere with leukemic cell mechanisms.
- Small molecular inhibitors show promise in overcoming chemo-resistance.
- Several novel agents are progressing through clinical trials and preclinical development.
Conclusions:
- Advances in understanding ALL biology are driving the development of targeted therapies.
- Small molecular inhibitors represent a promising strategy to improve adult ALL treatment outcomes.
- Overcoming challenges in drug development is crucial for successful clinical translation.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.